NCT05131477: Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study
- State
- Completed
- Phase
- Phase 2
- People
- 390 taking part
- Started
- 13 Dec 2021
- Primary completion
- 26 Apr 2023
- Arms
- 250mg (500mg Loading Dose) KY1005, 250mg (No Loading Dose) KY1005, 125mg KY1005, 62.5mg KY1005
- Results
- Posted on the registry
- Papers
- doi:10.1007/s13555-025-01609-6, doi:10.1016/j.jaci.2024.10.031, doi:10.1111/jdv.20877
- 23 Nov 2021: Trial registered
- 13 Dec 2021: Trial started
- 21 Feb 2024: Trial completed
- 3 Jul 2025: Trial results posted